Subscribe to RSS - BioScrip

BioScrip

BioScrip’s earnings decline

 - 
03/08/2018

DENVER – BioScrip reported net revenues of $182.6 million for the fourth quarter of 2017, down from $198.7 million in the third quarter.

Short takes: BioScrip, Rotech

 - 
01/10/2018

Denver-based BioScrip can now dispense and administer HEMLIBRA, a treatment for routine prophylaxis approved by the U.S. Food and Drug Administration.

BioScrip bolsters management team

 - 
11/28/2017

DENVER – BioScrip has added two new execs to its management team: Harriet Booker as senior vice president and COO, and Danny Claycomb as senior vice president of revenue cycle management.

‘Disruptors’ put a dent in BioScrip’s earnings

 - 
11/03/2017

DENVER – Company officials at BioScrip blamed a second straight quarter of net revenue declines on several “disrupters,” both expected and unexpected.

Short takes: BioScrip, Paragon Ventures, Stratice Healthcare, Invacare

 - 
10/05/2017

BioScrip is now dispensing and administering Radicava, the first treatment option for ALS approved by the U.S. Food and Drug Administration in more than 20 years…Paragon Ventures, a healthcare M&A firm, has launched paragonventures.com.

BioScrip revenues are down, but core product mix is up

 - 
08/11/2017

DENVER – BioScrip’s net revenues decreased 6.2% in the second quarter of 2017, but CEO Dan Greenleaf said in an earnings call the company was hitting targets.

BioScrip’s losses rack up in Q2

 - 
08/08/2017

DENVER – BioScrip reported net revenues of $218.1 million for the second quarter of 2017 compared to $232.4 million for the same period a year ago. Net loss was $29.2 million vs. $8.2 million.

In brief: Judge deals setback to Arriva Medical, BioScrip reports earnings

 - 
05/05/2017

CORAL SPRINGS, Fla. – Arriva Medical on April 25 lost an appeal seeking to reinstate its Medicare billing privileges, according to news reports.

BioScrip earnings ‘in line’ with expectations

 - 
05/05/2017

DENVER – BioScrip reported net revenues of $217.8 million for the first quarter of 2017, reflecting a core revenue mix of 72% compared to 60% during the same quarter in 2016. Net loss was $19 million and adjusted EBITD was 5.2 million.

'Clear mission' says Greenleaf

 - 
03/22/2017

With one full financial quarter under his belt, BioScrip President and CEO Dan Greenleaf says the company is reinvigorated and on track to right itself.

Pages